Full IRB Study Title:
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute,
330-543-3193 or email
research@akronchildrens.org